Go Pro
→ SPDR Gold just lost $14 billion. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.54
$4.57
$2.43
▼
$15.15
$4.03M0.71156,308 shs18,750 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.58
-0.6%		$6.04
$2.98
▼
$80.10
$3.72M2.7875,983 shs84,130 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.34
-4.1%		$2.10
$1.73
▼
$7.05
$4.25M0.739,871 shs24,230 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
0.00%-4.15%-40.24%-60.44%-73.56%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%-1.79%-24.37%-32.93%-82.84%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.00%+14.71%+15.84%+1.74%-42.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.54
$4.57
$2.43
▼
$15.15
$4.03M0.71156,308 shs18,750 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.58
-0.6%		$6.04
$2.98
▼
$80.10
$3.72M2.7875,983 shs84,130 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.34
-4.1%		$2.10
$1.73
▼
$7.05
$4.25M0.739,871 shs24,230 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
0.00%-4.15%-40.24%-60.44%-73.56%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%-1.79%-24.37%-32.93%-82.84%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.00%+14.71%+15.84%+1.74%-42.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.00
SellN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NMTR, XRTX, SILO, and SPRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
SciSparc Ltd. stock logo
SPRC
SciSparc
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/1/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/24/2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/11/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$70K57.69N/AN/A$3.08 per share0.82
SciSparc Ltd. stock logo
SPRC
SciSparc
$860K4.36N/AN/A$12.93 per share0.51
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/A$3.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-81.75%-66.35%9/2/2026 (Estimated)
SciSparc Ltd. stock logo
SPRC
SciSparc
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-$2.66M-$2.73N/AN/AN/AN/A-137.85%-108.16%11/12/2026 (Estimated)

Latest NMTR, XRTX, SILO, and SPRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32N/AN/AN/A$0.02 millionN/A
8/15/2026Q2 2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A-$1.05N/A-$1.05N/AN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
2.41
2.38
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A
3.58
3.58

Institutional Ownership

CompanyInstitutional Ownership
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.23%

Insider Ownership

CompanyInsider Ownership
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
21.59 million1.53 millionNot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4570,000557,000Not Optionable
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A1.82 million1.69 millionNot Optionable

Recent News About These Companies

XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed
August 28 at 12:11 PM  |  rttnews.comhttps://www.rttnews.com/3686444/xortx-slips-10-as-investor-relations-program-is-terminated-and-postponed.aspx
XORTX Announces Termination and Postponement of Investor Relations Program
August 28 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-files-august-form-6-k-highlighting-stronger-june-2026-balance-sheet?utm_source=marketbeat.com&utm_medium=referral
XORTX Therapeutics Inc.
August 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xrtx/company-people
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-announces-resignation-of-board-chairman-anthony-giovinazzo?utm_source=marketbeat.com&utm_medium=referral
XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur
August 2, 2026  |  zonebourse.comZ
XORTX Therapeutics Inc.: XORTX Announces Director Resignation
August 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69190082-xortx-therapeutics-inc-xortx-announces-director-resignation-399.htm
XORTX Announces Director Resignation
July 31, 2026  |  financialpost.comF
XORTX Announces Director Resignation
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3337071/0/en/xortx-announces-director-resignation.html
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-therapeutics-adds-independent-director-to-strengthen-board-oversight?utm_source=marketbeat.com&utm_medium=referral
XORTX Appoints New Director
July 29, 2026  |  financialpost.comF
XORTX Appoints New Director
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335091/0/en/xortx-appoints-new-director.html
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026  |  financialpost.comF
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311671/0/en/xortx-provides-corporate-update-and-announces-appointment-of-mika-grasso-as-co-ceo.html
XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing
June 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-to-voluntarily-delist-from-tsx-venture-exchange-maintain-nasdaq-listing?utm_source=marketbeat.com&utm_medium=referral
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026  |  financialpost.comF
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311334/0/en/xortx-announces-election-to-voluntary-delist-from-the-tsx-venture-exchange.html
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026  |  financialpost.comF
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297319/0/en/xortx-announces-closing-of-us-5-million-public-offering.html
XORTX files Q1 2026 unaudited results showing lower cash and equity
May 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xortx-files-q1-2026-unaudited-results-showing-lower-cash-and-equity?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$2.54 0.00 (0.00%)
As of 08/28/2026 03:59 PM Eastern

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$6.58 -0.04 (-0.60%)
As of 08/28/2026 03:51 PM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

XORTX Therapeutics stock logo

XORTX Therapeutics NASDAQ:XRTX

$2.34 -0.10 (-4.10%)
As of 08/28/2026 03:59 PM Eastern

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas